Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04433221 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination Immunotherapy Targeting Sarcomas

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 1, 2026 to Jul 1, 2027
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v4
  2. Study site revised
    • Collaborators shortened, about 8 words
    v3
  3. Primary completion date: May 31, 2023 to May 31, 2029v2 Show 4 more changesShow less
    • Start date: Jul 1, 2020 to Jul 1, 2026
    • Study sites: 2 to 1
    • Study completion date: Dec 31, 2023 to Dec 31, 2029
    • Collaborators: 2 to 1
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.
Trial Details
NCT Number NCT04433221
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
Related terms Bone Neoplasms, Sarcoma, Sarcoma, Ewing
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov